| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 1.77 | 47.9% | 0.6% |
| Total Income | 1.77 | 47.9% | 0.6% |
| Expenditure | 16.22 | 6.7% | 9.6% |
| PBT | — | ||
| Net Profit | -14.32 | 4.6% | 8.9% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.17 | 6.3% | 34.6% |
InspireMD Reports Q2 2026 Financial Results
17 Aug 2026 · 17 Aug, 4:41 pm
Summary
InspireMD reported second quarter 2026 revenue of $1.8 million, flat year-over-year, with international revenue showing robust growth of 21%. The company incurred a gross loss of $0.8 million due to recall-related charges, and total operating expenses increased by 2.5% to $13.7 million. Net loss for the quarter was $14.3 million, or $0.17 per share. For the first six months of 2026, revenue grew 56.3% to $5.2 million, and the company initiated cost-saving measures expected to yield $9 million annually.
Key Highlights
- 1
InspireMD generated revenue of $1.8 million in the second quarter of 2026, which was in line with the second quarter of 2025.
- 2
International revenue increased by 21% to $2.1 million in Q2 2026 compared to $1.8 million in Q2 2025.
- 3
The company reported a gross loss of $0.8 million for Q2 2026, impacted by an inventory impairment and customer credits related to a voluntary recall.
- 4
Total operating expenses for Q2 2026 were $13.7 million, a 2.5% increase compared to the prior year period.
- 5
Net loss for Q2 2026 was $14.3 million, or $0.17 per share, compared to a net loss of $13.2 million, or $0.26 per share, in Q2 2025.
- 6
For the first six months of 2026, total revenue increased by 56.3% to $5.2 million compared to $3.3 million in the same period of 2025.
- 7
The company initiated savings actions expected to generate annual savings of approximately $9 million.
Management Comments
Marvin Slosman
Following the end of the second quarter, we executed a series of steps designed to consolidate resources and better align our global operations with our near-term commercial and regulatory priorities, including streamlining our commercial organization to more effectively support our anticipated U.S. platform re-launch. We continue to engage in a productive dialogue with FDA regarding our pending regulatory submissions for our CGuard Prime 80 cm implant for TCAR procedures, as well as our original CGuard platform for traditional carotid stenting procedures. We continue to anticipate FDA decisions on both products later this year. At the same time, the design improvements that we are making to the CGuard Prime 135 cm delivery system, which we voluntarily recalled last quarter, are progressing as planned, with an FDA submission anticipated before year-end. Subject to receipt of the necessary regulatory approvals, we expect to return to the U.S. market with both TCAR and CAS delivery systems. We believe that this would strengthen our ability to compete in the carotid stenting market, and support increased adoption of the CGuard platform, expanded market penetration and future revenue growth, leveraging what we believe is a best-in-class implant in the carotid stenting space.
Informational and educational content only. Not investment advice.